Yes, Imjudo (tremelimumab) is FDA-approved for hepatocellular carcinoma (HCC), the most common type of liver cancer, in combination with Imfinzi (durvalumab).[1]
How is Imjudo approved for liver cancer?
The FDA granted accelerated approval in October 2022 for Imjudo plus Imfinzi as first-line treatment for unresectable HCC in adults, based on the HIMALAYA phase 3 trial. This showed a 22% reduction in death risk versus sorafenib, with median overall survival of 16.4 months versus 13.8 months.[1][2] Full approval depends on confirmatory trials.
What other liver cancer treatments does it compete with?
Imjudo/Imfinzi offers an immunotherapy alternative to single-agent sorafenib (Nexavar) or TKIs like lenvatinib. It's the first regimen to show superior survival over sorafenib in first-line advanced HCC. Lenvima/Keytruda is another approved immunotherapy combo, but HIMALAYA data positioned Imjudo/Imfinzi as a new standard option.[2]
Who makes Imjudo and when does its patent expire?
AstraZeneca develops and markets Imjudo. Key U.S. patents on tremelimumab expire in 2026 (composition of matter) with pediatric extensions possible to 2029, but formulation and method-of-use patents extend protection into the 2030s. No biosimilars are approved yet.[3]
What side effects do patients report with Imjudo for HCC?
Common immune-related adverse events include rash (up to 30%), diarrhea (20%), and hypothyroidism (15%). Severe cases (grade 3+) like hepatitis or pneumonitis occurred in 13% of HIMALAYA patients, often requiring steroids. Liver function monitoring is critical in HCC patients.[1][2]
[1]: FDA Approval Announcement for Imjudo + Imfinzi in HCC
[2]: HIMALAYA Trial Results (NEJM)
[3]: DrugPatentWatch.com - Tremelimumab Patents